Abstract:Adult-onset Still's disease (AOSD) is a multisystemic complex disorder clinically characterised by episodes of spiking fever, evanescent rash, polyarthritis or diffuse arthralgias; multiorgan involvement may develop according to the hyper-inflammatory extent. The pathogenesis of AOSD is not completely recognised. The central role of macrophage activation, which results in T helper 1 (Th1) cell cytokine activation, is well established. Pro-inflammatory cytokines such as interleukin (IL)-1, IL-6 and IL-18 play a fundamental role in disease onset and progression. The disease may develop in both children and adults with overlapping clinical features, and although several subsets depending on the clinical manifestations and the cytokines expressed have been identified, the dichotomy between systemic juvenile idiopathic arthritis (sJIA) and AOSD nowadays has been overcome, and the pathology is considered a disease continuum between ages. Various therapeutic approaches have been evaluated thus far, and different compounds are under assessment for AOSD treatment. Historically, glucocorticoids have been employed for treating systemic manifestations of Still's disease, while conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) demonstrated efficacy in controlling the articular manifestations. Currently, biological (b) DMARDs are widely employed; IL-1 inhibitors such as anakinra and canakinumab have proven to have high efficacy and an excellent safety profile and the anti-IL-6 tocilizumab is approved for sJIA, with several trials and longitudinal studies confirming its efficacy and safety. Moreover, in the light of the 'window of opportunity', new evidence showed that the earlier these treatments are initiated, the sooner clinical inactivity can be achieved. Other treatment options are being considered since several molecules involved in the disease pathophysiology can be targeted through various mechanisms. This review will provide a broad overview of AOSD pathophysiology, insights into specific organ manifestations and the currently available treatments with the identification of potential therapeutic targets involved in AOSD pathogenesis will be outlined.

A Case Report of JAK Inhibitors Therapy for Adult-Onset Still's Disease with Persistent Pruritic Lesions

Autoinflammatory Pathogenesis and Targeted Therapy for Adult-Onset Still’s Disease

Adult-Onset Still Disease Presenting With Dermatomyositis-Like Persistent Pruritic Lesions

Janus Kinase Inhibitor, Tofacitinib, in Refractory Juvenile Dermatomyositis: a Retrospective Multi-Central Study in China

The efficacy and safety of JAK inhibitors in patients with adult-onset still's disease: A meta-analysis and systematic review

The Efficacy of Baricitinib in Real-World Patients with Refractory or Severe Juvenile Dermatomyositis:A Monocentric Retrospective Study

Biological Therapy of Traditional Therapy-Resistant Adult-Onset Still’s Disease: an Evidence-Based Review

Histopathological Diagnosis of Persistent Pruritic Eruptions Associated with Adult-Onset Still's Disease.

Short-term Effectiveness of Baricitinib in Children with Refractory And/or Severe Juvenile Dermatomyositis.

Case Report: Adult Onset Still Disease in a 26-year-old Male

Janus kinase inhibition (JAKi) therapy in refractory anti-synthetase syndrome: A retrospective cohort study

Case Report: JAK1/2 Inhibition with Baricitinib in the Treatment of STING-associated Vasculopathy with Onset in Infancy.

JAK‐inhibitors for dermatomyositis: A concise literature review

Adult-Onset Still's Disease (AOSD): Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options

Clinical and immunological feature, therapeutic response and prognosis of adult onset Still's disease

JAK Inhibitors: Prospects in Connective Tissue Diseases

JAK Inhibitors in Psoriatic Disease

Adult-Onset Still's Disease (AOSD)—On the Basis of Own Cases

Dyskeratotic cells in persistent pruritic skin lesions as a prognostic factor in adult-onset Still disease

Unveiling the Mystery of Adult-Onset Still's Disease: A Compelling Case Report

[Update on Adult-Onset Still's Disease: Diagnosis, Therapy and Guideline]